Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
前日終値
$85.21
+$0.97 · +1.15%
時間外
$85.19
−$0.02 · -0.02%
10月9日 17:40 ET
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
34
割高
センチメント
65
強気
リスク
21
中程度のリスク
モメンタム
55
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
日中レンジ
現在 $85.21
52週レンジ
現在 $85.21
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 60.68億 USD | 54.4億 USD | 50.1億 USD | 53.82億 USD | 52.33億 USD |
| 売上原価 | 13.27億 USD | 11.18億 USD | 10.37億 USD | 11.67億 USD | 12.26億 USD |
| 粗利益 | 47.41億 USD | 43.22億 USD | 39.73億 USD | 42.15億 USD | 40.07億 USD |
| 研究開発 | 10.79億 USD | 10.53億 USD | 9.63億 USD | 9.45億 USD | 9.03億 USD |
| 販売・一般管理 | 20.85億 USD | 17.89億 USD | 15.83億 USD | 15.68億 USD | 14.93億 USD |
| 営業費用 | 31.05億 USD | 29.43億 USD | 25.45億 USD | 25.13億 USD | 23.96億 USD |
| 受取利息 | 1.48億 USD | 1.2億 USD | 6720万 USD | 3550万 USD | 1740万 USD |
| 支払利息 | — | 1980万 USD | 1760万 USD | 2620万 USD | 2480万 USD |
| 減価償却費と償却費 | 1.57億 USD | 1.55億 USD | 1.45億 USD | 1.4億 USD | 1.35億 USD |
| 営業利益 | 16.36億 USD | 13.79億 USD | 14.27億 USD | 17.02億 USD | 16.1億 USD |
| 純利益 | 10.74億 USD | 41.75億 USD | 14.02億 USD | 15.22億 USD | 15.03億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$101.7
上昇余地(19.35%)| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2020年6月1日 | 3:1 | — | — |
株式分割 | 2015年12月14日 | 2:1 | — | — |
株式分割 | 2010年5月28日 | 2:1 | — | — |
発効済み 2020年6月1日
3:1
発効済み 2015年12月14日
2:1
発効済み 2010年5月28日
2:1
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。